The U.S. Food and Drug Administration (FDA) sometimes gets lost in a bureaucratic maze of confusion and red tape that deprives patients of beneficial therapies. Innovative products sometimes fall within a gray area and become overly regulated. One of the FDA’s latest targets is regenerative medicine.
An article titled, An MBA in Regulatory Confusion, talks about Florida-based Regenative Labs. The firm manufactures products made from umbilical cords (donated by mothers after a C-section, according to the company website). English physician and anatomist Thomas Wharton first described his namesake umbilical cord jelly in 1656, although he had no way of knowing it is rich in stem cells and regenerative healing properties.